In addition, relative to parental venetoclax, two of our lead compounds, BD‐4‐213 and AMC‐4‐154, exhibited superior activities against the acute myeloid leukemia cell line MV4;11 and an MV4;11 cell line engineered to overexpress BCL‐2. This evidence concerns the gene BCL2 and acute myeloid leukemia.